Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven Rottenberg

Showing results (11-20 of 121) with videos related to

Pageof 13
Sort By:
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 4, 2018
New tools for old drugs: Functional genetic screens to optimize current chemotherapyNora M Gerhards, Sven Rottenberg
Nature Reviews. Cancer|October 31, 2020
The rediscovery of platinum-based cancer therapySven Rottenberg, Carmen Disler, Paola Perego
Cell Cycle (Georgetown, Tex.)|April 18, 2008
How do real tumors become resistant to cisplatin?Piet Borst, Sven Rottenberg, Jos Jonkers
Current Opinion in Microbiology|August 28, 2003
Theileria-induced leukocyte transformationDirk A E Dobbelaere, Sven Rottenberg
Methods in Molecular Biology (Clifton, N.J.)|December 2, 2009
Studying drug resistance using genetically engineered mouse models for breast cancerSven Rottenberg, Marina Pajic, Jos Jonkers
Cell Cycle (Georgetown, Tex.)|November 14, 2007
What makes tumors multidrug resistant?Piet Borst, Jos Jonkers, Sven Rottenberg
Frontiers in Genetics|March 7, 2022
Meiotic Genes and DNA Double Strand Break Repair in CancerLea Lingg, Sven Rottenberg, Paola Francica
STAR Protocols|February 11, 2022
Functional genetic dropout screens and <i>in vivo</i> validation of candidate therapeutic targets using mouse mammary tumoroidsMariana Paes Dias, Sven Rottenberg, Jos Jonkers
Biochimica Et Biophysica Acta|July 21, 2009
Therapeutic options for triple-negative breast cancers with defective homologous recombinationJanneke E Jaspers, Sven Rottenberg, Jos Jonkers
Frontiers in Oncology|May 21, 2020
Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient CancersMartin Liptay, Joana S Barbosa, Sven Rottenberg
Pageof 13

Showing results (11-20 of 121) with videos related to

Sort By:
Pageof 13
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 4, 2018
New tools for old drugs: Functional genetic screens to optimize current chemotherapyNora M Gerhards, Sven Rottenberg
Nature Reviews. Cancer|October 31, 2020
The rediscovery of platinum-based cancer therapySven Rottenberg, Carmen Disler, Paola Perego
Cell Cycle (Georgetown, Tex.)|April 18, 2008
How do real tumors become resistant to cisplatin?Piet Borst, Sven Rottenberg, Jos Jonkers
Current Opinion in Microbiology|August 28, 2003
Theileria-induced leukocyte transformationDirk A E Dobbelaere, Sven Rottenberg
Methods in Molecular Biology (Clifton, N.J.)|December 2, 2009
Studying drug resistance using genetically engineered mouse models for breast cancerSven Rottenberg, Marina Pajic, Jos Jonkers
Cell Cycle (Georgetown, Tex.)|November 14, 2007
What makes tumors multidrug resistant?Piet Borst, Jos Jonkers, Sven Rottenberg
Frontiers in Genetics|March 7, 2022
Meiotic Genes and DNA Double Strand Break Repair in CancerLea Lingg, Sven Rottenberg, Paola Francica
STAR Protocols|February 11, 2022
Functional genetic dropout screens and <i>in vivo</i> validation of candidate therapeutic targets using mouse mammary tumoroidsMariana Paes Dias, Sven Rottenberg, Jos Jonkers
Biochimica Et Biophysica Acta|July 21, 2009
Therapeutic options for triple-negative breast cancers with defective homologous recombinationJanneke E Jaspers, Sven Rottenberg, Jos Jonkers
Frontiers in Oncology|May 21, 2020
Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient CancersMartin Liptay, Joana S Barbosa, Sven Rottenberg
Pageof 13